Pegfilgrastim biosimilar - Dong-A ST

Drug Profile

Pegfilgrastim biosimilar - Dong-A ST

Alternative Names: DA-3031; DA-3031 (PEG-G-CSF) - Dong-A; Dulastin; PEG-filgrastim - Dong-A; Pegfilgrastim biosimilar - Dong-A; Pegylated-G-CSF - Dong-A; Tripegfilgrastim - Dong-A

Latest Information Update: 18 Nov 2016

Price : $50

At a glance

  • Originator Dong-A Pharmaceutical
  • Developer Dong-A ST
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Polyethylene glycols; Proteins; Recombinant proteins
  • Mechanism of Action Granulocyte stimulants; Haematopoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Neutropenia

Highest Development Phases

  • Marketed Neutropenia

Most Recent Events

  • 01 Sep 2016 Phase-I clinical trials in Neutropenia (In children, In adolescents, Chemotherapy-induced) in South Korea (SC) (NCT02963389)
  • 08 May 2015 Launched for Neutropenia (Chemotherapy-induced) in South Korea (SC)
  • 22 Oct 2013 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top